PRJNA497977
C57BL/6J mouse Metagenome
This study assessed the impact of 2 anti-diabetic therapies on the gut microbiome and markers of cardiometabolic disease risk in mice. Diet-induced obese and diabetic C57BL/6J mice were treated with 1 of 2 antidiabetic therapeutics—metformin or a DPP-4 inhibitor (PKF-275-055) for 12 weeks.